Dario Kivelevitch, MD
Dermatology · Lancaster, TXNPI 1922485838
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Boehringer Ingelheim at 52.9% of the total. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,382 payments — averaging $160.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$118K
- Johnson & Johnson$28K
- Novartis$20K
- Lilly USA, LLC$19K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- UCB, Inc.$7K
- plus $23K from 34 others
Across 4 payments — averaging $4438.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$13K
- Novartis$4K
What the payments were for
- Consulting fees$73,07733%
- Speaking & faculty fees$104,86947%
- Travel & lodging$14,4276%
- Food & beverage$29,55613%
- Education$5180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$222,445 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 14 | $95,362 |
| Humira(Cf) PenAdalimumab | 12 | $81,735 |
| Dupixent PenDupilumab | 14 | $63,189 |
| Clobetasol Propionate | 100 | $5,665 |
| Acitretin | 14 | $3,230 |
| Dutasteride | 36 | $1,109 |
| Ketoconazole | 74 | $1,106 |
| Tretinoin | 14 | $863 |
| Triamcinolone Acetonide | 68 | $794 |
| Doxycycline Monohydrate | 29 | $589 |
| ValacyclovirValacyclovir Hcl | 13 | $574 |
| Minoxidil | 46 | $548 |
| Clotrimazole | 22 | $391 |
| Doxycycline Hyclate | 30 | $352 |
| MethotrexateMethotrexate Sodium | 17 | $338 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Lancaster
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.